XML 43 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1

Collaboration Agreements (Tables)

6 Months Ended

Jun. 29, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration Revenues and Contract Assets and Liabilities

Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2018				2017				2018				2017
Ipsen collaboration revenues	$	34,043			$	5,494			$	87,852			$	10,024

Royalties accruing to GSK in connection with the sales of COMETRIQ and CABOMETYX are included in Cost of goods sold for net sales by us and as a reduction of Collaboration revenues for net sales by Ipsen on the accompanying Condensed Consolidated Statements of Operations. Such royalties were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2018				2017				2018				2017
Royalties accruing to GSK	$	5,628			$	2,962			$	10,753			$	5,363

Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2018				2017				2018				2017
Takeda collaboration revenues	$	1,986			$	4,143			$	4,903			$	6,825

Royalty revenues on ex-U.S. sales and our share of the profits and losses recognized in connection with COTELLIC’s commercialization in the U.S. were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2018				2017				2018				2017
Royalty revenues on ex-U.S. sales	$	1,546			$	1,367			$	2,895			$	3,665
Profits and losses on U.S. commercialization	$	2,696			$	(781	)		$	4,069			$	(1,407	)

X

- References

No definition available.

+ Details

Name:	us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration